Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Praram 9 Hospital PCLBKK:PR9 +1.04%96 3-Year EBITDA Growth Rate is 9.90% as of Jun. 2026, which is 4% below its 10-year median of 10.30. GuruFocus rates BKK:PR9 with a GF Score™ of 96/100 and a GF Value™ of ฿23.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 525 Healthcare Providers & Services companies, Praram 9 Hospital PCL ranks worse than 50.1% on this metric.
During the past 12 months, Praram 9 Hospital PCL's average EBITDA Per Share Growth Rate was 3.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -16.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Praram 9 Hospital PCL was 481.00% per year. The lowest was -80.70% per year. And the median was 10.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Praram 9 Hospital PCL 3-Year EBITDA Growth Rate Related Terms
BKK:PR9 vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Praram 9 Hospital PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praram 9 Hospital PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Praram 9 Hospital PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Praram 9 Hospital PCL's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.90% mean?
Praram 9 Hospital PCL (BKK:PR9) has a 3-Year EBITDA Growth Rate of 9.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Praram 9 Hospital PCL and its competitors. This is near median its historical median of 10.30. According to the industry distribution chart, Praram 9 Hospital PCL ranks #263 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 50.1%.
Is Praram 9 Hospital PCL's 3-Year EBITDA Growth Rate too high?
Praram 9 Hospital PCL's current 3-Year EBITDA Growth Rate of 9.90% is near median its 10-year median of 10.30. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Praram 9 Hospital PCL's value of 9.90% is 0% at this industry median. Based on the distribution chart, Praram 9 Hospital PCL ranks #263 out of 525 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Praram 9 Hospital PCL has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Praram 9 Hospital PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Praram 9 Hospital PCL ranks #263 out of 525 companies for 3-Year EBITDA Growth Rate. This places Praram 9 Hospital PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Praram 9 Hospital PCL's value of 9.90% is 0% at this benchmark. While the company's 10-year median is 10.30 vs. the industry median of 9.90, Praram 9 Hospital PCL has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Praram 9 Hospital PCL's current 3-Year EBITDA Growth Rate of 9.90% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Praram 9 Hospital PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Praram 9 Hospital PCL's current 3-Year EBITDA Growth Rate is 9.90%, which is near median its own 10-year median of 10.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praram 9 Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, Praram 9 Hospital PCL (BKK:PR9) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿23.34, compared to a current price of ฿19.50 — trading 16.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.90%, which is near median its 10-year median of 10.30 and 0% at the Healthcare Providers & Services industry median of 9.90. Praram 9 Hospital PCL's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Praram 9 Hospital PCL (BKK:PR9), the current 3-Year EBITDA Growth Rate is 9.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Praram 9 Hospital PCL (BKK:PR9) Overvalued in 2026?
Based on GuruFocus' analysis, Praram 9 Hospital PCL stock appears to be undervalued.
The current stock price of ฿19.50 is trading 16.5% below its estimated GF Value™ of ฿23.34.
GuruFocus considers Praram 9 Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:PR9:
3-Year EBITDA Growth Rate: 9.90% (near median its 10-year median of 10.30)
GF Value™: ฿23.34 vs. price of ฿19.50 (16.5% below fair value)
Industry Position: 0% at the Healthcare Providers & Services median (#263 of 525)
No single metric tells the full story. See the BKK:PR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Praram 9 Hospital PCL is engaged in hospital operations in Bangkok. The company operates an overnight general hospital under the name of Praram 9 Hospital. The revenue derived from hospital operations mainly consists of medical fees, hospital room sales, and medicine sales. Geographically, the company operates only in Thailand.
96GF Score
Get the complete analysis for BKK:PR9
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:PR9 has been successfully added to your 
